RE: 🔥🔥🔥 AML TREATMENT28 Feb 2025 16:38
With the first patient showing no adverse effects so far, Hemogenyx is hopeful about the progress of HG-CT-1 and is ready to scale up manufacturing as new patients are identified.
Dr. Vladislav Sandler: After the infusion of any patient, there are 28 days designated as the so-called official safety trial. During these 28 days, the patient is tested several times for adverse effects of this cell therapy. As a secondary readout, we also look at the efficacy or potential efficacy of this treatment. At this point, after a few days post-infusion, we did not have bad news, which is good news. Anything adverse happening must be reported to us, and if it is a severe adverse side effect, it must be reported to the FDA. So far, we assume everything is in line, and everything is good.
In practice, we can start manufacturing for the next patient literally today, however, we are waiting for the hospital to find that next patient. The research is ongoing already. From this point on, we expect acceleration of the process and the acceleration of the clinical trial.